BioStem Technologies, Inc. (BSEM) Misses Q1 EPS by 41c, provides guidance

BioStem Technologies, Inc. (OTC: BSEM) reported Q1 EPS of ($0.39), $0.41 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $10.1 million versus the consensus estimate of $55.2 million.

GUIDANCE:

BioStem Technologies, Inc. sees Q1 2026 revenue of $5-6 million.

For earnings history and earnings-related data on BioStem Technologies, Inc. (BSEM) click here.

You May Also Be Interested In

• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
• BK Technologies (BKTI) Tops Q2 EPS by 11c
• Bending Spoons S.p.A. (BSP) Tops Q2 EPS by 19c; offers guidance